Category Press Releases

BUILT Biotechnologies Named Anchor Company at Commonwealth BioAccelerator Amid DNA Manufacturing Growth

BUILT Biotechnologies Named Anchor Company at Commonwealth BioAccelerator, Scaling DNA Manufacturing-as-a-Service to Meet Surging Demand BUILT Biotechnologies,a rapidly emerging leader in DNA Manufacturing-as-a-Service, has announced its selection as an anchor company at the Commonwealth BioAccelerator, an initiative spearheaded by CvilleBioHub…

Read MoreBUILT Biotechnologies Named Anchor Company at Commonwealth BioAccelerator Amid DNA Manufacturing Growth

Alpha Cognition Inc. Prices $35 Million Oversubscribed Public Offering of Common Shares

Alpha Cognition Inc. Announces Pricing of $35 Million Oversubscribed Public Offering of Common Shares Alpha Cognition Inc. (Nasdaq: ACOG) (the “Company”), a commercial-stage biopharmaceutical company committed to advancing innovative therapies for neurodegenerative diseases, today announced the pricing of its oversubscribed…

Read MoreAlpha Cognition Inc. Prices $35 Million Oversubscribed Public Offering of Common Shares

FIRE1 Norm System Congestion Score Highlighted as Late-Breaking Science at HFSA 2025

FIRE1’s Norm System and Congestion Score Highlighted as Late-Breaking Science at HFSA 2025 FIRE1, a pioneering company in connected medical device solutions, has announced that its innovative heart failure management program, encompassing the FUTURE-HF and FUTURE-HF2 trials, has been selected…

Read MoreFIRE1 Norm System Congestion Score Highlighted as Late-Breaking Science at HFSA 2025

Endeavor BioMedicines Shares Positive Phase 2a Taladegib Data

Endeavor BioMedicines Reports Positive Phase 2a Results for Taladegib in Idiopathic Pulmonary Fibrosis, Published in The Lancet Respiratory Medicine Endeavor BioMedicines (“Endeavor”), a clinical-stage biotechnology company focused on developing transformative therapies for life-threatening diseases, has announced the publication of Phase…

Read MoreEndeavor BioMedicines Shares Positive Phase 2a Taladegib Data

HELIOS-B Phase 3: Vutrisiran Shows Fewer GI Events in ATTR-CM Patients

Alnylam Pharmaceuticals Reports HELIOS-B Phase 3 Findings: Vutrisiran Reduces Gastrointestinal Events in ATTR-CM Patients Alnylam Pharmaceuticals, Inc. , a global leader in RNA interference (RNAi) therapeutics, today unveiled new analyses from the HELIOS-B Phase 3 study evaluating AMVUTTRA® (vutrisiran). Vutrisiran…

Read MoreHELIOS-B Phase 3: Vutrisiran Shows Fewer GI Events in ATTR-CM Patients

Cytokinetics Opens Submissions for 8th Annual Communications Grant Program

Cytokinetics Announces Call for Proposals for Its Eighth Annual Communications Grant Program Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the eighth annual Cytokinetics Communications Grant Program. The program will award five grants to patient advocacy organizations…

Read MoreCytokinetics Opens Submissions for 8th Annual Communications Grant Program